The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy

Baris Bingol (), Joy S. Tea, Lilian Phu, Mike Reichelt, Corey E. Bakalarski, Qinghua Song, Oded Foreman, Donald S. Kirkpatrick and Morgan Sheng
Additional contact information
Baris Bingol: Genentech, Inc., South San Francisco, California 94080, USA
Joy S. Tea: Genentech, Inc., South San Francisco, California 94080, USA
Lilian Phu: Genentech, Inc., South San Francisco, California 94080, USA
Mike Reichelt: Genentech, Inc., South San Francisco, California 94080, USA
Corey E. Bakalarski: Genentech, Inc., South San Francisco, California 94080, USA
Qinghua Song: Genentech, Inc., South San Francisco, California 94080, USA
Oded Foreman: Genentech, Inc., South San Francisco, California 94080, USA
Donald S. Kirkpatrick: Genentech, Inc., South San Francisco, California 94080, USA
Morgan Sheng: Genentech, Inc., South San Francisco, California 94080, USA

Nature, 2014, vol. 510, issue 7505, 370-375

Abstract: Abstract Cells maintain healthy mitochondria by degrading damaged mitochondria through mitophagy; defective mitophagy is linked to Parkinson’s disease. Here we report that USP30, a deubiquitinase localized to mitochondria, antagonizes mitophagy driven by the ubiquitin ligase parkin (also known as PARK2) and protein kinase PINK1, which are encoded by two genes associated with Parkinson’s disease. Parkin ubiquitinates and tags damaged mitochondria for clearance. Overexpression of USP30 removes ubiquitin attached by parkin onto damaged mitochondria and blocks parkin’s ability to drive mitophagy, whereas reducing USP30 activity enhances mitochondrial degradation in neurons. Global ubiquitination site profiling identified multiple mitochondrial substrates oppositely regulated by parkin and USP30. Knockdown of USP30 rescues the defective mitophagy caused by pathogenic mutations in parkin and improves mitochondrial integrity in parkin- or PINK1-deficient flies. Knockdown of USP30 in dopaminergic neurons protects flies against paraquat toxicity in vivo, ameliorating defects in dopamine levels, motor function and organismal survival. Thus USP30 inhibition is potentially beneficial for Parkinson’s disease by promoting mitochondrial clearance and quality control.

Date: 2014
References: Add references at CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://www.nature.com/articles/nature13418 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:510:y:2014:i:7505:d:10.1038_nature13418

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature13418

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().